热门资讯> 正文

CytoMed Therapeutics报告FY结果

2025-04-29 22:10

CytoMed Therapeutics Limited(GDTC) 0

CytoMed Therapeutics press release (NASDAQ:GDTC): FY topline income amounted to $624,771 in 2024 compared to $588,423 in 2023.
Cash and bank balances amounted to US$3.64 million as of December 31, 2024.
Excluding costs associated with being a public company listed on the NASDAQ Capital Market amounting to $188,341, the company recorded a reduced net loss of $1.66 million for the financial year ended December 31, 2024.

More on CytoMed Therapeutics;

Seeking Alpha’s Quant Rating on CytoMed Therapeutics 
Historical earnings data for CytoMed Therapeutics 
Financial information for CytoMed Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。